Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Tuberculosis | Research

Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF-β1 siRNA for improving spinal tuberculosis therapy

Authors: Zongqiang Yang, Caili Lou, Xuewei Wang, Chaoran Wang, Zhiyun Shi, Ningkui Niu

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Tuberculosis (TB) represents a bacterial infection affecting many individuals each year and potentially leading to death. Overexpression of transforming growth factor (TGF)-β1 has a primary immunomodulatory function in human tuberculosis. This work aimed to develop nanoliposomes to facilitate the delivery of anti-tubercular products to THP-1-derived human macrophages as Mycobacterium host cells and to evaluate drug efficiencies as well as the effects of a TGF-β1-specific short interfering RNA (siRNA) delivery system employing nanoliposomes.

Methods

In the current study, siTGF-β1 nanoliposomes loaded with the anti-TB drugs HRZ (isoniazid, rifampicin, and pyrazinamide) were prepared and characterized in vitro, determining the size, zeta potential, morphology, drug encapsulation efficiency (EE), cytotoxicity, and gene silencing efficiency of TGF-β1 siRNA.

Results

HRZ/siTGF-β1 nanoliposomes appeared as smooth spheres showing the size and positive zeta potential of 168.135 ± 0.5444 nm and + 4.03 ± 1.32 mV, respectively. Drug EEs were 90%, 88%, and 37% for INH, RIF, and PZA, respectively. Meanwhile, the nanoliposomes were weakly cytotoxic towards human macrophages as assessed by the MTT assay. Nanoliposomal siTGF-β1 could significantly downregulate TGF-β1 in THP-1-derived human macrophages in vitro.

Conclusion

These findings suggested that HRZ-loaded nanoliposomes with siTGF-β1 have the potential for improving spinal tuberculosis chemotherapy via nano-encapsulation of anti-TB drugs.
Literature
1.
Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global tuberculosis report 2020 -reflections on the global TB burden, treatment and prevention efforts. INT J INFECT DIS. 2021;113(1):1–57.
2.
Costa A, Pinheiro M, Magalhaes J, Ribeiro R, Seabra V, Reis S, et al. The formulation of nanomedicines for treating tuberculosis. Adv Drug Deliv Rev. 2016;102:102–15.PubMedCrossRef
3.
Saifullah B, El Zowalaty ME, Arulselvan P, Fakurazi S, Webster TJ, Geilich BM, et al. Synthesis, characterization, and efficacy of antituberculosis isoniazid zinc aluminum-layered double hydroxide based nanocomposites. Int J Nanomedicine. 2016;11:3225–37.PubMedPubMedCentralCrossRef
4.
Ivancic A, Macaev F, Aksakal F, Boldescu V, Pogrebnoi S, Duca G. Preparation of alginate-chitosan-cyclodextrin micro- and nanoparticles loaded with anti-tuberculosis compounds. Beilstein J Nanotechnol. 2016;7:1208–18.PubMedPubMedCentralCrossRef
5.
Broderick C, Hopkins S, Mack DJF, Aston W, Pollock R, Skinner JA, et al. Delays in the diagnosis and treatment of bone and joint tuberculosis in the United Kingdom. Bone Joint J. 2018;100-b(1):119–24.PubMedCrossRef
6.
Niu N, Wang Q, Shi J, Zhang X, Geng G, Zhou S, et al. Clinical and genomic responses to ultra-short course chemotherapy in spinal tuberculosis. Exp Ther Med. 2017;13(5):1681–8.PubMedPubMedCentralCrossRef
7.
Jin W, Wang Q, Wang Z, Geng G. Complete debridement for treatment of thoracolumbar spinal tuberculosis: a clinical curative effect observation. Spine J. 2014;14(6):964–70.PubMedCrossRef
8.
Si J, Geng G, Wang Z. Detection of Mycobacterium tuberculosis DNA in the sclerotic spinal wall. Orthopedics. 2012;35(3):e409-413.PubMedCrossRef
9.
Shi J, Wang Z, Li H, Yuan H. Diagnostic performance of the urinary deoxypyridinoline in spinal tuberculosis. Orthopedics. 2012;35(6):e922-926.PubMedCrossRef
10.
Geng G, Wang Q, Shi J, Yan J, Niu N, Wang Z. Establishment of a New Zealand rabbit model of spinal tuberculosis. J Spinal Disord Tech. 2015;28(3):E140-145.PubMedCrossRef
11.
Shi JD, Wang ZL, Geng GQ, Niu NK. Intervertebral focal surgery for the treatment of non-contiguous multifocal spinal tuberculosis. Int Orthop. 2012;36(7):1423–7.PubMedPubMedCentralCrossRef
12.
Ge Z, Wang Z, Wei M. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis. Eur Spine J. 2008;17(11):1482–7.PubMedPubMedCentralCrossRef
13.
Shi JD, Wang Q, Wang ZL. Primary issues in the selection of surgical procedures for thoracic and lumbar spinal tuberculosis. Orthop Surg. 2014;6(4):259–68.PubMedPubMedCentralCrossRef
14.
Si J, Wang Z, Wang Z, Li H. Sequencing-based detection of drug-resistant Mycobacterium tuberculosis in patients with spinal tuberculosis. Arch Orthop Trauma Surg. 2012;132(7):941–5.PubMedCrossRef
15.
Wang Z, Ge Z, Jin W, Qiao Y, Ding H, Zhao H, et al. Treatment of spinal tuberculosis with ultrashort-course chemotherapy in conjunction with partial excision of pathologic vertebrae. Spine J. 2007;7(6):671–81.PubMedCrossRef
16.
Wang Z, Shi J, Geng G, Qiu H. Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation. Eur Spine J. 2013;22(2):274–81.PubMedCrossRef
17.
Farooq MA, Aquib M, Farooq A, Haleem Khan D, Joelle Maviah MB, Sied Filli M, et al. Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. Artif Cells Nanomed Biotechnol. 2019;47(1):1674–92.PubMedCrossRef
18.
Karimi M, Zare H, Bakhshian Nik A, Yazdani N, Hamrang M, Mohamed E, et al. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond). 2016;11(5):513–30.CrossRef
19.
20.
Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H, et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457–501.PubMedPubMedCentralCrossRef
21.
Saifullah B, Chrzastek A, Maitra A, Naeemullah B, Fakurazi S, Bhakta S, et al. Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide. Molecules. 2017;22(10).
22.
Gao Y, Sarfraz MK, Clas SD, Roa W, Lobenberg R. Hyaluronic acid-tocopherol succinate-based self-assembling micelles for targeted delivery of rifampicin to alveolar macrophages. J Biomed Nanotechnol. 2015;11(8):1312–29.PubMedCrossRef
23.
Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA. pH-responsive isoniazid-loaded nanoparticles markedly improve tuberculosis treatment in mice. Small. 2015;11(38):5066–78.PubMedPubMedCentralCrossRef
24.
Mohseni M, Gilani K, Mortazavi SA. Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery. Iran J Pharm Res. 2015;14(1):27–34.PubMedPubMedCentral
25.
Toossi Z, Ellner JJ. The role of TGF beta in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol. 1998;87(2):107–14.PubMedCrossRef
26.
Bonecini-Almeida MG, Ho JL, Boechat N, Huard RC, Chitale S, Doo H, et al. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun. 2004;72(5):2628–34.PubMedPubMedCentralCrossRef
27.
Aung H, Toossi Z, McKenna SM, Gogate P, Sierra J, Sada E, et al. Expression of transforming growth factor-beta but not tumor necrosis factor-alpha, interferon-gamma, and interleukin-4 in granulomatous lung lesions in tuberculosis. Tuber Lung Dis. 2000;80(2):61–7.PubMedCrossRef
28.
Hirsch CS, Yoneda T, Averill L, Ellner JJ, Toossi Z. Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis. 1994;170(5):1229–37.PubMedCrossRef
29.
Kumar NP, Moideen K, George PJ, Dolla C, Kumaran P, Babu S. Coincident diabetes mellitus modulates Th1-, Th2-, and Th17-cell responses in latent tuberculosis in an IL-10- and TGF-beta-dependent manner. Eur J Immunol. 2016;46(2):390–9.PubMedCrossRef
30.
Kalita J, Misra UK, Bhoi SK, Chauhan PS, Sagar B. Possible role of transforming growth factor beta in tuberculous meningitis. Cytokine. 2017;90:124–9.PubMedCrossRef
31.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–11.PubMedCrossRef
32.
Mirahadi M, Ghanbarzadeh S, Ghorbani M, Gholizadeh A, Hamishehkar H. A review on the role of lipid-based nanoparticles in medical diagnosis and imaging. Ther Deliv. 2018;9(8):557–69.PubMedCrossRef
33.
Kong X, Liu Y, Huang X, Huang S, Gao F, Rong P, et al. Cancer therapy based on smart drug delivery with advanced nanoparticles. Anticancer Agents Med Chem. 2019;19(6):720–30.PubMedCrossRef
34.
Ivashchenko O, Coy E, Peplinska B, Jarek M, Lewandowski M, Zaleski K, et al. Influence of silver content on rifampicin adsorptivity for magnetite/Ag/rifampicin nanoparticles. Nanotechnology. 2017;28(5): 055603.PubMedCrossRef
35.
Kumar A, Sharma R, Nair A, Saini G. Development and validation of RP-HPLC method for simultaneous estimation of nimesulide, phenylephrine hydrochloride, chlorpheniramine maleate and caffeine anhydrous in pharmaceutical dosage form. Acta Pol Pharm. 2012;69(6):1017–22.PubMed
36.
Clemens DL, Lee BY, Xue M, Thomas CR, Meng H, Ferris D, et al. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob Agents Chemother. 2012;56(5):2535–45.PubMedPubMedCentralCrossRef
37.
Shaikh MV, Kala M, Nivsarkar M. Formulation and optimization of doxorubicin loaded polymeric nanoparticles using Box-Behnken design: ex-vivo stability and in-vitro activity. Eur J Pharm Sci. 2017;100:262–72.PubMedCrossRef
38.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.PubMedCrossRef
39.
Chay SY, Tan WK, Saari N. Preparation and characterisation of nanoliposomes containing winged bean seeds bioactive peptides. J Microencapsul. 2015;32(5):488–95.PubMedCrossRef
40.
Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur J Pharm Biopharm. 2015;89:163–74.PubMedCrossRef
41.
Hirsch V, Kinnear C, Moniatte M, Rothen-Rutishauser B, Clift MJ, Fink A. Surface charge of polymer coated SPIONs influences the serum protein adsorption, colloidal stability and subsequent cell interaction in vitro. Nanoscale. 2013;5(9):3723–32.PubMedCrossRef
42.
Schaeublin NM, Braydich-Stolle LK, Schrand AM, Miller JM, Hutchison J, Schlager JJ, et al. Surface charge of gold nanoparticles mediates mechanism of toxicity. Nanoscale. 2011;3(2):410–20.PubMedCrossRef
43.
Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv. 2010;7(7):781–94.PubMedCrossRef
44.
Chen R, Han Z, Huang Z, Karki J, Wang C, Zhu B, et al. Antibacterial activity, cytotoxicity and mechanical behavior of nano-enhanced denture base resin with different kinds of inorganic antibacterial agents. Dent Mater J. 2017;36(6):693–9.PubMedCrossRef
45.
Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials. 2010;31(26):6867–75.PubMedCrossRef
46.
Jain AK. Tuberculosis of the spine: a fresh look at an old disease. J Bone Joint Surg Br. 2010;92(7):905–13.PubMedCrossRef
47.
Gehlot PS, Chaturvedi S, Kashyap R, Singh V. Pott’s spine: retrospective analysis of MRI scans of 70 cases. J Clin Diagn Res. 2012;6(9):1534–8.PubMedPubMedCentral
48.
Li L, Xu J, Ma Y, Tang D, Chen Y, Luo F, et al. Surgical strategy and management outcomes for adjacent multisegmental spinal tuberculosis: a retrospective study of forty-eight patients. Spine. 2014;39(1):E40-48.PubMedCrossRef
49.
Sequeira W, Co H, Block JA. Osteoarticular tuberculosis: current diagnosis and treatment. Am J Ther. 2000;7(6):393–8.PubMedCrossRef
50.
Dunn RN, Husien MB. Spinal tuberculosis: review of current management. Bone Joint J. 2018;100-b(4):425–31.PubMedCrossRef
51.
Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516–28.PubMedCrossRef
52.
53.
Schaberg T. The dark side of antituberculosis therapy: adverse events involving liver function. Eur Respir J. 1995;8(8):1247–9.PubMedCrossRef
54.
Huang D, Li D, Wang T, Shen H, Zhao P, Liu B, et al. Isoniazid conjugated poly(lactide-co-glycolide): long-term controlled drug release and tissue regeneration for bone tuberculosis therapy. Biomaterials. 2015;52:417–25.PubMedCrossRef
55.
Li D, Li L, Ma Y, Zhuang Y, Li D, Shen H, et al. Dopamine-assisted fixation of drug-loaded polymeric multilayers to osteoarticular implants for tuberculosis therapy. Biomater Sci. 2017;5(4):730–40.PubMedCrossRef
56.
Xie X, Liao J, Shao X, Li Q, Lin Y. The effect of shape on cellular uptake of gold nanoparticles in the forms of stars, rods, and triangles. Sci Rep. 2017;7(1):3827.PubMedPubMedCentralCrossRef
57.
Hiroi K, Kura H, Ogawa T, Takahashi M, Sato T. Magnetic ordered states induced by interparticle magnetostatic interaction in alpha-Fe/Au mixed nanoparticle assembly. J Phys Condens Matter. 2014;26(17): 176001.PubMedCrossRef
58.
Nigam K, Kaur A, Tyagi A, Manda K, Gabrani R, Dang S. Baclofen-loaded poly (D, L-Lactide-Co-Glycolic Acid) nanoparticles for neuropathic pain management: in vitro and in vivo evaluation. Rejuvenation Res. 2019;22(3):235–45.PubMedCrossRef
59.
Kumar S, Ali J, Baboota S. Design Expert((R)) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. Nanotechnology. 2016;27(43): 435101.PubMedCrossRef
60.
Bhattacharjee S, de Haan LH, Evers NM, Jiang X, Marcelis AT, Zuilhof H, et al. Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells. Part Fibre Toxicol. 2010;7:25.PubMedPubMedCentralCrossRef
61.
Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul. 1995;12(3):229–46.PubMedCrossRef
62.
Barenholz Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J Liposome Res. 2003;13(1):1–8.PubMedCrossRef
63.
Gorgizadeh M, Azarpira N, Dehdari Veis R, Sattarahmady N. Repression of melanoma tumor in vitro and in vivo by photothermal effect of carbon xerogel nanoparticles. Colloids Surf B Biointerfaces. 2019;176:449–55.PubMedCrossRef
64.
Amaral EP, Lasunskaia EB, D’Imperio-Lima MR. Innate immunity in tuberculosis: how the sensing of mycobacteria and tissue damage modulates macrophage death. Microbes Infect. 2016;18(1):11–20.PubMedCrossRef
65.
Sia JK, Georgieva M, Rengarajan J. Innate immune defenses in human tuberculosis: an overview of the interactions between Mycobacterium tuberculosis and innate immune cells. J Immunol Res. 2015;2015: 747543.PubMedPubMedCentralCrossRef
66.
Niimi T, Sato S, Sugiura Y, Yoshinouchi T, Akita K, Maeda H, et al. Transforming growth factor-beta gene polymorphism in sarcoidosis and tuberculosis patients. Int J Tuberc Lung Dis. 2002;6(6):510–5.PubMedCrossRef
67.
Limper AH, Colby TV, Sanders MS, Asakura S, Roche PC, DeRemee RA. Immunohistochemical localization of transforming growth factor-beta 1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med. 1994;149(1):197–204.PubMedCrossRef
68.
69.
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–6.PubMedCrossRef
70.
Zhou J, Shum KT, Burnett JC, Rossi JJ. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals (Basel). 2013;6(1):85–107.CrossRef
Metadata
Title
Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF-β1 siRNA for improving spinal tuberculosis therapy
Authors
Zongqiang Yang
Caili Lou
Xuewei Wang
Chaoran Wang
Zhiyun Shi
Ningkui Niu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07791-8

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue

Research

Safety of a Novel ESAT6-CFP10 skin test compared with tuberculin skin test in a double-blind, randomized, controlled study

Research

Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru

Research article

Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study

Review

Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use

Research

Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort

Research

Analytical estimation of maximum fraction of infected individuals with one-shot non-pharmaceutical intervention in a hybrid epidemic model
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits